A new study published in The Journal of Infection found that the long-acting monoclonal antibody nirsevimab (Beyfortus) provides protection against respiratory syncytial virus (RSV) infection in children under 2 years of age for up to one year, but its effectiveness may not extend beyond that period.

Lower respiratory tract infections in newborns and young children are still frequently caused by the respiratory syncytial virus, which frequently results in hospitalization and long-term respiratory problems. Conventional preventative interventions, such palivizumab, are restricted to high-risk newborns and need regular administration.

A single intramuscular dosage of nirsevimab, a long-acting monoclonal antibody that targets the RSV fusion protein, offers prolonged protection, marking a

See Full Page